Compound class:
Synthetic organic
Comment: Laniquidar (R101933) is a third generation inhibitor of the ATP-binding cassette transporter P-glycoprotein (P-gp; ABCB1) [1-2]. P-gp is a drug transporter and efflux pump that can promote resistance to drugs, including chemotherapeutics. Pharmacologic inhibition of P-gp is an established strategy that is being investigated to block this resistance mechanism in cancers [1].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate |
International Nonproprietary Names ![]() |
|
INN number | INN |
8067 | laniquidar |
Database Links ![]() |
|
CAS Registry No. | 197509-46-9 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL539378 |
DrugBank Ligand | DB12799 |
GtoPdb PubChem SID | 458923824 |
PubChem CID | 6450806 |
Search Google for chemical match using the InChIKey | TULGGJGJQXESOO-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | TULGGJGJQXESOO |
Search PubMed clinical trials | laniquidar |
Search PubMed titles | laniquidar |
Search PubMed titles/abstracts | laniquidar |
UniChem Compound Search for chemical match using the InChIKey | TULGGJGJQXESOO-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | TULGGJGJQXESOO-UHFFFAOYSA-N |